Biomoda Inc., An In-Vitro Diagnostics Company, Enters into Agreement with Cytomyx, LLC, a Leader in Translational Medicine.

ALBUQUERQUE, N.M. -- Biomoda Will Be Aided in Its Product Validation Efforts By Cytomyx, LLC, A Recognized World Leader in Products and Services for Translational Medicine 

Biomoda Inc. and Cytomyx, LLC, of Lexington, Mass., www.cytomyx.com, have entered into an agreement for Cytomyx, LLC, to provide human clinical samples to Biomoda for its diagnostic test development program.

Validation studies for Biomoda's patented and patent-pending products for the early detection and targeted treatment of specific cancers will be supported by its relationship with Cytomyx, LLC.

"Cytomyx has one of the largest human tissue collections which makes them an ideal strategic partner for Biomoda. The clinical samples from Cytomyx are of the highest quality. Cytomyx has two main areas of expertise: the use of human clinical samples in understanding the linkage between gene expression and disease, and the development of cell-based assays," said John Cousins, president of Biomoda. Biomoda is interested in developing cancer diagnostic products in both of these strategic market spaces. "We are very excited about this alliance."

About Biomoda

Biomoda Inc., a development stage in-vitro diagnostics organization, is focused on research, development and commercialization of cancer diagnostics. The company has several patents developed for noninvasive early detection and treatment of specific cancers, and is in the process of registering additional patents in this area. The company's proprietary technologies provide minimally invasive and minimal-impact approaches as cancer diagnostic products. Biomoda's laboratory operations are situated at Kirtland Air Force Base (Albuquerque, N.M.). For more information visit www.biomoda.com.

About Cytomyx

Cytomyx, LLC, a division of Cytomyx Holdings PLC, is a rapidly growing life science company based in Cambridge, United Kingdom, and Lexington, Mass. The company's primary focus is on developing novel technologies that assist pharmaceutical and biotechnology companies in their efforts to develop new treatments more effectively. The company does this by providing solutions that provide early insights into the likely efficacy and safety profile of new drugs in development. The company has two main areas of expertise: the use of human clinical samples in understanding the linkage between gene expression and disease, and the development of cell-based assays that are used to support ion channel drug discovery and predict potential cardiac toxicity in new drugs. Cytomyx is listed on the AIM market of the London Stock Exchange (CYX.L). For more information visit www.cytomyx-holdings.com.

This news release contains forward-looking statements that involve a high degree of risk and uncertainty. Such statements include, but are not limited to, statements containing the words "believes," "anticipates," "expects," "estimates," and words of similar import. The company's actual results could differ materially from any forward-looking statements, which reflect management's opinions only as of the date of this report, as a result of risks and uncertainties that exist in our operation, development efforts and business environment. The company undertakes no obligation to revise or publicly release the results of any revisions to these forward-looking statements. You should carefully review the risk factors in other documents that the company files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. For additional information, visit the Biomoda Web site at www.biomoda.com or call us at 505-821-0875.